RecruitingPhase 2NCT04899687

Study of Dextromethorphan in OCD and Related Disorders

Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study


Sponsor

Stanford University

Enrollment

60 participants

Start Date

Jan 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether dextromethorphan (an ingredient found in some cough medicines) can reduce symptoms in people with obsessive-compulsive disorder (OCD) or related conditions that involve excessive worry about body appearance or physical symptoms. **You may be eligible if...** - You have been diagnosed with OCD, body dysmorphic disorder, illness anxiety disorder, or somatic symptom disorder - You live in California - You are able to provide informed consent **You may NOT be eligible if...** - You have a current diagnosis of bipolar disorder or a psychotic disorder - You have a moderate or severe substance use problem (current or severe history) - You are pregnant or nursing - You are taking prescription psychiatric medications other than fluoxetine - You have recently started OCD-specific therapy (exposure and response prevention) within the past 2 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFluoxetine

Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks

DRUGDextromethorphan

Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.


Locations(1)

Stanford University

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04899687


Related Trials